We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Verona Pharma Plc | LSE:VRP | London | Ordinary Share | GB00BYW2KH80 | ORD 5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 55.00 | 45.00 | 65.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
TIDMVRP
LONDON, April 16, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP)
(Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical
company focused on developing and commercializing innovative therapies
for respiratory diseases, announces that all resolutions proposed at the
Annual General Meeting held today were duly approved by shareholders by
way of a poll. The
https://www.globenewswire.com/Tracker?data=UZ7F2WI6AhjjP-g8XncEHkPGqQZKVHjl0OmoQDCw5GzvbJMAlkuH71ptZjp7I0QDsbreVWQlVhwd5ssfchksOWtf9cNKfR7rooTyyyDn-IyvAczeGRroBY4mJuCwKML9PbP8uVM7yXcqpYaikxYWyw==
results of the poll are available on the Investors section of the
Company's website, www.veronapharma.com.
About Verona Pharma
Verona Pharma is a clinical-stage biopharmaceutical company focused on
developing and commercializing innovative therapies for the treatment of
respiratory diseases with significant unmet medical needs. If
successfully developed and approved, Verona Pharma's product candidate,
ensifentrine, has the potential to be the first therapy for the
treatment of respiratory diseases that combines bronchodilator and
anti-inflammatory activities in one compound. Verona Pharma is currently
evaluating three formulations of ensifentrine for the treatment of COPD
in Phase 2 clinical trials: nebulized, dry powder inhaler, and
pressurized metered-dose inhaler. Ensifentrine also has potential
applications in cystic fibrosis, asthma and other respiratory diseases.
For more information, please visit www.veronapharma.com.
For further information, please contact:
Verona Pharma plc Tel: +44 (0)20 3283 4200
-------------------------------------------- -------------------------
Victoria Stewart, Director of Communications info@veronapharma.com
-------------------------------------------- -------------------------
N+1 Singer Tel: +44 (0)20 3283 4200
-------------------------------------------- -------------------------
(Nominated Adviser and UK Broker)
Aubrey Powell / George Tzimas / Iqra
Amin (Corporate Finance)
Tom Salvesen (Corporate Broking)
-------------------------------------------- -------------------------
Optimum Strategic Communications Tel: +44 (0)20 3950 9144
(European Media and Investor Enquiries) verona@optimumcomms.com
-------------------------------------------- -------------------------
Mary Clark / Eva Haas / Hollie Vile
-------------------------------------------- -------------------------
Argot Partners Tel: +1 212-600-1902
(US Investor Enquiries) verona@argotpartners.com
-------------------------------------------- -------------------------
Stephanie Marks / Kimberly Minarovich /
Michael Barron
-------------------------------------------- -------------------------
(END) Dow Jones Newswires
April 16, 2020 07:12 ET (11:12 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Verona Pharma Chart |
1 Month Verona Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
